Navigation Links
Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
Date:10/15/2007

LAVAL, QC, Oct. 15 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB), is pleased to announce the appointment of a dynamic new Scientific Advisory Board (the "Advisory Board"), comprised of 5 renowned scientists.

Neptune believes that the combined knowledge and experience of the new members of the Advisory Board will significantly contribute to Neptune's scientifically driven growth. Neptune feels privileged to build its new Scientific Advisory Board with a group of such distinguished scientists.

a. Steven E. Nissen, M.D., MACC, is the Chairman of the Cleveland Clinic

Department of Cardiovascular Medicine, and Immediate Past President,

American College of Cardiology, Washington, DC. He previously served

as the Medical Director of the Clinic's Cardiovascular Coordinating

Center. Dr. Nissen has stipulated that he receive no personal

compensation for participation in the Advisory Board and that any

consulting fees be paid directly to charity.

b. Magdy M. Abdel-Malik, Ph.D., is the president of Quaestio Global

Partners LLC (Quaestio GP), as the Director, Global External

Opportunities, Pfizer Consumer Healthcare, Morris Plains, NJ.

Dr. Abdel-Malik identified and secured external products and

technologies achieving above-market growth for the $4B Pfizer Consumer

Healthcare business.

c. Thomas G. Hartman, Ph.D. has served for the past 22 years as Mass

Spectrometry Lab Manager at the Rutgers University Center for Advanced

Food Technology (CAFT). Dr. Hartman has served as an analytical and

technical consultant to over 250 companies and many government

agencies. He is a member of the American Society of Mass Spectrometry

(ASMS), American Chemical Society (ACS) and the Agricultural and Food

Chemistry Division, American Association for the Advancement of

Science (AAAS) and Institute of Food Technologists (IFT).

d. Demian Barbas B.Sc., Ph.D., has particular expertise in biochemistry,

biotechnology, intellectual property law and patents in life sciences.

Dr. Barbas is currently practising at Ogilvy Renault LLP/S.E.N.C.R.L.,

s.r.l., and is a member of the American Society for Biochemistry and

Molecular Biology (ASBMB) and an affiliate of the Intellectual

Property Institute of Canada (IPIC).

e. Melvin Dionne B.Sc. Pharm., has been the president of Services

Pharmaceutiques Melvin Dionne Inc since 1999. He has a strong

background in regulatory affairs and quality control in the

pharmaceutical industry, with particular expertise in pharmaceutical

company compliance with Health Canada and FDA regulations for product

and site licensing.

"I feel extremely honoured to be working with such an eminent group of scientists and profiting from their guidance and valuable advice while developing and building our product pipeline and growing in the nutraceutical and pharmaceutical worlds" said Dr. Tina Sampalis, Vice-President Research and Business Development of Neptune.

About Neptune Technologies & Bioressources Inc.

Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the nutraceutical and pharmaceutical health and wellness market. The Company develops and markets new formulas and new products for specific applications in high growth markets such the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products.

The TSX.V has not reviewed and does not accept responsibility for the

adequacy and accuracy of this news release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from the historical results, from any future results expressed, or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission.


'/>"/>
SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW-Madisons Beebe wins scientific award
2. Researchers say scientific reporting needs more perspective, less hype
3. Wisconsin stands at the center of scientific efforts to avert flu epidemics
4. Growth prompts new location for scientific instrument manufacturer
5. UW stem cell guru outlines scientific and political future
6. Wisconsin biotech sector featured in scientific magazine
7. Scientific Protein Laboratories Acquired by New York firm
8. GenTel Appoints Burke to its Scientific Advisory Board
9. Sharon Ethanol appoints operations director
10. Stratagem acquires the Milwaukee operations of BORN
11. Rockwell Q2 operations net income soars, shares plunge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):